EMA Advisory Committee Recommends Novo Nordisk’s Insulin Combination
By

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Xultophy for the treatment of Type 2 diabetes mellitus in adults.

Xultophy is the intended brand name for IDegLira,  the first once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), developed for the treatment of Type 2 diabetes. The CHMP positive opinion recommends that Xultophy will be indicated for the treatment of adults with Type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.

Source: Novo Nordisk

Leave a Reply

Your email address will not be published. Required fields are marked *